{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T08:14:00Z","timestamp":1760170440639,"version":"3.33.0"},"reference-count":37,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2007,8,16]],"date-time":"2007-08-16T00:00:00Z","timestamp":1187222400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2007,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Objective:<\/jats:bold>Evaluate the incidence of mental disorders using pegylated interferon plus ribavirin retreatment in nonresponder hepatitis C virus\u2010infected patients.<\/jats:p><jats:p><jats:bold>Method:<\/jats:bold>The Mini\u2010International Neuropsychiatric Interview (MINI) was used to evaluate 30 hepatitis C virus\u2010infected interferon\u2010nonresponder patients at baseline and following 4, 12 and 24 weeks of pegylated interferon retreatment.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold>During the pegylated interferon\/ribavirin retreatment, 5(16.6%) patients developed psychiatric side effects: 3(10%) were diagnosed with major depressive disorder, 1(3.3%) had a brief psychotic disorder and 1(3.3%) presented with panic attacks.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold>This is the first prospective study evaluating the incidence of neuropsychiatric side effects during interferon retreatment of hepatitis C virus\u2010infected patients, suggesting that the risk of acquiring serious psychiatric symptoms during retreatment with interferon\u2010\u03b1 (IFN\u2010\u03b1) may not be higher than during the first antiviral therapy. This finding challenges the hypothesis that during a second treatment with IFN\u2010\u03b1, patients with hepatitis C may be at greater risk for neuropsychiatric side effects than na\u00efve patients.<\/jats:p>","DOI":"10.1111\/j.1478-3231.2007.01532.x","type":"journal-article","created":{"date-parts":[[2007,8,17]],"date-time":"2007-08-17T21:51:25Z","timestamp":1187387485000},"page":"1098-1102","source":"Crossref","is-referenced-by-count":21,"title":["Incidence of psychiatric side effects during pegylated interferon\u2010 \u03b1 retreatment in nonresponder hepatitis C virus\u2010infected patients"],"prefix":"10.1111","volume":"27","author":[{"given":"Lucas C.","family":"Quarantini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo A.","family":"Bressan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Galv\u00e3o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"Batista\u2010Neves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymundo","family":"Paran\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c2ngela","family":"Miranda\u2010Scippa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,8,16]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"958","article-title":"Peginterferon alfa\u20102b plus ribavirin compared with interferon alfa\u20102b plus ribavirin for initial treatment of chronic hepatitis C","volume":"358","author":"Manns MP","year":"2001","journal-title":"a randomized trial"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020047"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0676.2003.00838.x"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0676.2003.00836.x"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2004.0954.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811193392101"},{"issue":"1","key":"e_1_2_6_8_2","doi-asserted-by":"crossref","first-page":"S237","DOI":"10.1002\/hep.1840360730","article-title":"Side effects of therapy of hepatitis C and their management","volume":"36","author":"Fried MW.","year":"2002","journal-title":"Hepatology"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1022449613907"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.35950"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.161.12.2331"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.156.7.1120"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4001119"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n0614"},{"key":"e_1_2_6_15_2","first-page":"34","article-title":"Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon\u2010alpha therapy","volume":"25","author":"Horikawa N","year":"2003","journal-title":"a prospective study"},{"key":"e_1_2_6_16_2","first-page":"284","article-title":"Assessment of depression in patients with chronic hepatitis","volume":"20","author":"Koskinas J","year":"2002","journal-title":"effect of interferon treatment"},{"key":"e_1_2_6_17_2","first-page":"473","article-title":"Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C","volume":"26","author":"Bodenheimer HC","year":"1997","journal-title":"a multicenter trial"},{"key":"e_1_2_6_18_2","first-page":"41","article-title":"Depression during pegylated interferon\u2010alpha plus ribavirin therapy","volume":"66","author":"Raison CL","year":"2005","journal-title":"prevalence and prediction"},{"key":"e_1_2_6_19_2","first-page":"455","article-title":"Interferon\u2010alpha and transforming growth factor\u2010beta 1 regulate corticotrophin\u2010releasing factor release from the amygdala","volume":"30","author":"Raber J","year":"1997","journal-title":"comparison with the hypothalamic response"},{"key":"e_1_2_6_20_2","first-page":"296","article-title":"The role of corticotrophin\u2010releasing\u2010factor in the pathophysiology of affective and anxiety disorders","volume":"172","author":"Owens MJ","year":"1993","journal-title":"Laboratory and clinical studies"},{"key":"e_1_2_6_21_2","first-page":"1367","article-title":"Corticosteroid feedback control of ACTH secretion","volume":"92","author":"Dallman MF","year":"1973","journal-title":"effect of stress-induced corticosterone secretion on subsequent stress responses in the rat"},{"key":"e_1_2_6_22_2","first-page":"204","article-title":"Cognitive impairment in patients with chronic hepatitis treated with interferon alpha (IFN\u2010\u03b1)","volume":"21","author":"Lieb K","year":"2006","journal-title":"results from a prospective study"},{"key":"e_1_2_6_23_2","first-page":"106","article-title":"Mini International Neuropsychiatric Interview (MINI)","volume":"22","author":"Amorim P.","year":"2000","journal-title":"validation of a short structured diagnostic psychiatric interview"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.genhosppsych.2005.05.012"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)04793-X"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1987.00370090055011"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.32104"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(87)91319-5"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1999.00857.x"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199606273342602"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1998.225_a.x"},{"key":"e_1_2_6_32_2","first-page":"115","article-title":"Hepatitis C, alpha interferon, anxiety and depression disorders","volume":"4","author":"Gohier B","year":"2003","journal-title":"a prospective study of 71 patients"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2005.01.020"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2005.00554.x"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199904293401716"},{"key":"e_1_2_6_36_2","first-page":"138","article-title":"Effect of amantadine on depressive symptoms in chronic hepatitis C patients treated with pegylated interferon","volume":"29","author":"Quarantini LC","year":"2006","journal-title":"a randomized, controlled pilot study"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21302"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2004.04.002"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1478-3231.2007.01532.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1478-3231.2007.01532.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T12:41:00Z","timestamp":1737376860000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1478-3231.2007.01532.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,16]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["10.1111\/j.1478-3231.2007.01532.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1478-3231.2007.01532.x","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"type":"print","value":"1478-3223"},{"type":"electronic","value":"1478-3231"}],"subject":[],"published":{"date-parts":[[2007,8,16]]}}}